Document:

Exhibit 4.4

 

AMENDMENT TO

TAPIMMUNE INC.

2014 OMNIBUS STOCK OWNERSHIP PLAN, 

AS AMENDED THROUGH AUGUST 29, 2017

 

WHEREAS, the 2014 Omnibus Stock Ownership
Plan (the “Plan”) was originally adopted by the Company and approved by the stockholders on August 29, 2017;

 

WHEREAS, on May 14, 2018, the Board
of Directors approved an amendment to increase the shares authorized and available under the Plan by 6,616,666 shares (the “Amendment”)
and authorized the submission of the Amendment to the stockholders for approval; and

  

WHEREAS, on August 29, 2017, the stockholders
approved the Amendment to the Plan at the Company’s annual meeting and the shares authorized under the Plan were increased
by 6,616,666 shares from 1,383,334 shares to 8,000,000.

 

NOW THEREFORE, Section 3.a titled
“Scope of the Plan” is amended as follows:

 

The reference to “1,383,334” is replaced with “8,000,000”,
to reflect the approved increase in the shares reserved under the Plan.

 

All other terms and conditions of the Plan
remain in full force and effect.

 

IN WITNESS WHEREOF, the Company has
caused its duly authorized officer to sign this Amendment to the TapImmune Inc. 2014 Omnibus Stock Ownership Plan on its behalf.

 

	 	TAPIMMUNE INC. 

 

	 	 
	 	Michael Loiacono, Chief Financial OfficerExhibit 10.3

 

BOARD OBSERVER AND DIRECTOR NOMINATION
AGREEMENT

 

THIS BOARD OBSERVER
AND DIRECTOR NOMINATION AGREEMENT (this “Agreement”) is made as of October 17, 2018 (the “Effective
Date”), between MARKER THERAPEUTICS, INC., a Delaware corporation formerly known as TapImmune Inc., a Nevada corporation
(the “Company”), and NEW ENTERPRISE ASSOCIATES, INC. (the “Shareholder”). Unless
otherwise specified herein, all of the capitalized terms used herein are defined in Section 3 hereof.

 

WHEREAS, effective
as of the Effective Date, the Shareholder has purchased 5,000,000 shares of common stock, par value, $0.001 per share, of the Company
(“Common Stock”) in a private placement of the Company with a group of institutional investors for an
aggregate of 17,500,000 shares of Common Stock; and

 

WHEREAS, the
Company has agreed to permit the Shareholder, for so long as the Shareholder Beneficially Owns at least 2,500,000 shares of Common
Stock, par value, $0.001 per share, of the Company (the “Company Shares”), to have the right to designate
one person as a board observer or to designate one person for nomination for election to the board of directors of the Company
(the “Board”), subject to the terms and conditions set forth in this Agreement.

 

NOW, THEREFORE,
in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties to this Agreement hereby agree as follows:

 

Section 1.             Board
Observer and Nominee to Board of Directors.

 

(a)          Subject
to the terms and conditions of this Agreement, from and after the Effective Date and until a Termination Event (as defined below)
shall have occurred, the Shareholder shall have the right, effective immediately, to designate one person to be either (i) appointed
as a board observer (“Board Observer”), or (ii) appointed or nominated, as the case may be, for election
to the Board (including any successor, each, a “Nominee”). The Shareholder shall exercise these rights,
in its sole discretion, from time to time by providing written notice to the Company. Ali Behbahani is hereby designated by the
Shareholder to serve as a Board Observer, effective as of the Effective Date.

 

(b)          If
the Shareholder has elected to designate one Board Observer, the Board Observer shall have the right to attend and participate
in all meetings of the Board in a non-voting capacity, and the Company shall provide such Board Observer copies of all notices,
consents, minutes and other materials, financial or otherwise, which the Company provides to the Board, provided, however,
that if the Board Observer does not, upon the written request of the Company, before attending any meetings of the Board, execute
and deliver to the Company an agreement to abide by all Company policies applicable to members of the Board and a confidentiality
agreement reasonably acceptable to the Company, the Board Observer may be excluded from access to any material or meeting or portion
thereof if the Board determines in good faith, upon advice of counsel, that such exclusion is reasonably necessary to protect highly
confidential proprietary information of the Company or confidential proprietary information of third parties that the Company is
required to hold in confidence, or for other similar reasons. The Shareholder may revoke the designation of any person as the Board
Observer at any time upon written notice to the Company after which the Shareholder shall be entitled to designate a replacement
Board Observer.

 

     

     

    

 

(c)          A
Board Observer shall serve under the terms of the Board Observer and Indemnification Agreement attached hereto as Exhibit 1
with such changes as may be agreed upon by the Company and the Board Observer.

 

(d)          At
the sole discretion of the Shareholder, from and after the Effective Date and until a Termination Event shall have occurred, in
lieu of designating a Board Observer, the Shareholder shall have the right to designate a Nominee to serve as a member of the Board.
If the Shareholder provides written notice to the Company that it is exercising its right to designate a Nominee, the Company shall,
as promptly as practicable, take all necessary and desirable actions within its control (including, without limitation, increasing
the size of the Board, calling special meetings of the Board and the shareholders of the Company and recommending, supporting and
soliciting proxies) to allow the Nominee to serve as a member of the Board. Such actions shall include ensuring that: (i) the Nominee
is included in the Board’s slate of nominees to the shareholders of the Company for each election of Directors; and (ii)
the Nominee is included in the proxy statement prepared by management of the Company in connection with soliciting proxies for
every meeting of the shareholders of the Company called with respect to the election of members of the Board, and at every adjournment
or postponement thereof, and on every action or approval by written resolution of the shareholders of the Company or the Board
with respect to the election of members of the Board.

 

(e)          If
the Shareholder designates a Nominee to serve as a member of the Board, and such Nominee is thereafter appointed or elected to
the Board, then the right of the Shareholder to appoint a Board Observer shall automatically terminate so long as the Nominee is
serving as a member of the Board. If NEA has designated a person as a Board Observer, and thereafter designates a different person
as a Nominee who becomes a member of the Board, then such person designated as Board Observer may continue in such capacity on
an “at will” basis, until such time as the Board takes an affirmative action to remove such person as a Board Observer
at the Board’s sole discretion.

 

(f)          Notwithstanding
anything herein to the contrary, the Company shall not be obligated to cause to be nominated for election to the Board or recommend
to the stockholders the election of any Nominee: (i) who fails to submit to the Company on a timely basis such questionnaires as
the Company may reasonably require of its directors generally and such other information as the Company may reasonably request
in connection with the preparation of its filings under the Securities Laws; (ii) if the Board or the nominating committee (if
any) determines in good faith, after consultation with outside legal counsel, that such action would constitute a breach of its
fiduciary duties or applicable Law or violate the Company’s Certificate of Incorporation; or (iii) unless such Nominee meets
the Board’s reasonable standards for Directors generally and complies with the Board’s policies applicable to all Directors
(it being understand that such Nominee shall not be required by the Board to be independent of the Company); provided, however,
that, the Company shall promptly notify the Shareholder of the occurrence of such event and permit the Shareholder to provide an
alternate Nominee sufficiently in advance of any Board action or any meetings of the Company’s shareholders called for the
purpose of electing members of the Board, but in no event shall the Company be obligated to postpone, reschedule or delay any scheduled
meeting of the Company’s shareholders with respect to such election of members of the Board.

 

    	 	2	 

     

    

 

(g)          If
a vacancy occurs, or a Nominee fails to be elected, in either case because of the death, disability, disqualification, resignation
or removal of a Nominee or for any other reason, the Shareholder shall be entitled to designate such person’s successor,
and the Company shall, within ten (10) days of such designation, take all necessary and desirable actions within its control such
that such vacancy shall be filled with such successor Nominee, it being understood that any such successor designee shall serve
the remainder of the term of the director whom such designee replaces. The Shareholder shall not be obligated to designate a director
Nominee pursuant to this Agreement but the failure to do so shall not constitute a waiver of its rights hereunder.

 

(h)          The
Company shall pay the reasonable, documented out-of-pocket expenses incurred by each Board Observer or Nominee in connection with
his or her services provided to or on behalf of the Company, including attending meetings (including committee meetings) or events
attended on behalf of the Company at the Company’s request.

 

(i)          The
Company shall (i) purchase directors’ and officers’ liability insurance in an amount determined by the Board to be
reasonable and customary and (ii) for so long as any Board Observer serves in such capacity, or a Nominee nominated pursuant to
the terms of this Agreement serves as a member of the Board, maintain such coverage with respect to such members of the Board and/or
Board Observer.

 

(j)          For
so long as any Nominee serves as a member of the Board, the Company shall not amend, alter or repeal any right to indemnification
or exculpation covering or benefiting any Nominee nominated pursuant to this Agreement as and to the extent consistent with applicable
law, including but not limited to any provisions of the Company Charter (whether such right is contained in the Company Charter
or another document) (except to the extent such amendment or alteration permits the Company to provide broader indemnification
or exculpation rights on a retroactive basis than permitted prior thereto).

 

Section 2.            Termination.
Notwithstanding anything to the contrary contained herein, upon (i) a Change of Control Transaction, or (ii) the Shareholder (together
with its Affiliates and permitted assignees) ceases to Beneficially Own less than 2,500,000 Company Shares (“Termination
Event”), then this Agreement shall expire and terminate automatically; provided, however, that Sections
1(h), (i), and (j) and Sections 11 and 12 shall survive the termination of this Agreement.

 

Section 3.            Definitions.

 

“Affiliate”
means, with respect to any Person, any other Person that directly, or indirectly through one or more intermediaries, controls,
is controlled by, or is under common control with, such first Person.

 

“Agreement”
has the meaning set forth in the preamble.

 

    	 	3	 

     

    

 

“Beneficially
Own” has the meaning ascribed to it in Section 13(d) of the Securities Exchange Act of 1934, as amended.

 

“Board”
has the meaning set forth in the recitals.

 

“Board Observer”
has the meaning set forth in Section 1(a).

 

“Business
Day” means any day that is not a Saturday, Sunday, legal holiday or other day on which commercial banks in New York,
New York are authorized or required by applicable law to close.

 

“Change of
Control Transaction” means a merger, consolidation or other similar transaction or series of transactions to which
the Company is a party, regardless of whether the Company is the surviving Person in such transaction, pursuant to which the holders
of shares of Common Stock immediately prior to such transaction (including for this purpose the Shares issuable on conversion of
notes and exercise of options and warrants ) represent less than 50% of the shares of Common Stock outstanding immediately following
such transaction.

 

“Common Stock”
has the meaning set forth in the recitals.

 

“Company
Shares” has the meaning set forth in the recitals.

 

“Company”
has the meaning set forth in the preamble.

 

“Company
Charter” means the Company’s Certificate of Incorporation, as in effect at the Effective Date, as the same
may be amended from time to time.

 

“Effective
Date” has the meaning set forth in the preamble.

 

“Nominee”
has the meaning set forth in Section 1(a).

 

“Person”
means an individual, a partnership, a corporation, a limited liability company, an association, a joint stock company, a trust,
a joint venture, an unincorporated organization and a governmental entity or any department, agency or political subdivision thereof.

 

“Shareholder”
has the meaning set forth in the preamble.

 

“Termination
Event” has the meaning set forth in Section 3.

 

“Transfer”
means any sale, transfer, assignment or other disposition of (whether with or without consideration and whether voluntary or involuntary
or by operation of law) of Company Shares.

 

Section 4.            Assignment;
Benefit of Parties; Transfer. This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and
their respective successors, legal representatives and assignees for the uses and purposes set forth and referred to herein. Notwithstanding
the foregoing, the Company may not assign any of its rights or obligations hereunder without the prior written consent of the Shareholder.
Nothing herein contained shall confer or is intended to confer on any third party or entity that is not a party to this Agreement
any rights under this Agreement.

 

    	 	4	 

     

    

 

Section 5.            Remedies.
The Company and the Shareholder shall be entitled to enforce their rights under this Agreement specifically, to recover damages
by reason of any breach of any provision of this Agreement and to exercise all other rights existing in their favor. The parties
hereto agree and acknowledge that a breach of this Agreement would cause irreparable harm and money damages may not be an adequate
remedy for any such breach and that, in addition to other rights and remedies hereunder, the Company and the Shareholder shall
be entitled to specific performance and/or injunctive or other equitable relief (without posting a bond or other security) from
any court of law or equity of competent jurisdiction in order to enforce or prevent any violation of the provisions of this Agreement.

 

Section 6.            Notices.
Any notice provided for in this Agreement shall be in writing and shall be either personally delivered, or mailed first class mail
(postage prepaid, return receipt requested) or sent by reputable overnight courier service (charges prepaid) to the Company and
the Shareholder at the addresses set forth below. Notices shall be deemed to have been given hereunder when delivered personally,
three days after deposit in the U.S. mail and one day after deposit with a reputable overnight courier service.

 

		(a)	If to the Company:

 

Marker Therapeutics,
Inc.

5 W. Forsyth
Street, Suite 200

Jacksonville
FL 32202

Attention:
CEO

 

with a copy
to:

 

Seyfarth Shaw
LLP

700 Milam,
Suite 1400

Houston TX
77002

Attention:
Paul Pryzant

 

		(b)	If to the Shareholder:

 

New Enterprise Associates, Inc.

5425 Wisconsin Ave, Suite 800

Chevy Chase, MD 20815

Attention: Ali Behbahani

 

with a copy to:

 

New Enterprise Associates, Inc.

5425 Wisconsin Ave, Suite 800

Chevy Chase, MD 20815

Attention: Chief Legal Officer

 

    	 	5	 

     

    

 

Section 7.            Adjustments.
If, and as often as, there are any changes in the Common Stock by way of stock split, stock dividend, combination or reclassification,
or through merger, consolidation, reorganization, recapitalization or sale, or by any other means, appropriate adjustment shall
be made in the provisions of this Agreement, as may be required, so that the rights, privileges, duties and obligations hereunder
shall continue with respect to the Company Shares as so changed.

 

Section 8.            No
Third-Party Beneficiaries. Nothing in this Agreement, express or implied, is intended or shall be construed to confer upon,
or give to, any person or entity other than the parties hereto and their respective successors and assigns any remedy or claim
under or by reason of this Agreement or any terms, covenants or conditions hereof, and all of the terms, covenants, conditions,
promises and agreements contained in this Agreement shall be for the sole and exclusive benefit of the parties hereto and their
respective successors and assigns.

 

Section 9.             Further
Assurances. Each of the parties hereby agrees that it will hereafter execute and deliver any further document, agreement, instruments
of assignment, transfer or conveyance as may be necessary or desirable to effectuate the purposes hereof.

 

Section 10.          Counterparts.
This Agreement may be executed in one or more counterparts, and may be delivered by means of facsimile or electronic transmission
in portable document format, each of which shall be deemed to be an original and shall be binding upon the party who executed the
same, but all of such counterparts shall constitute the same agreement.

 

Section 11.           Governing
Law. All issues and questions concerning the construction, validity, interpretation and enforceability of this Agreement and
the exhibits and schedules hereto shall be governed by, and construed in accordance with, the laws of the State of Delaware, without
giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction)
that would cause the application of the laws of any jurisdiction other than the State of Delaware.

 

Section 12.           Mutual
Waiver of Jury Trial. THE PARTIES HERETO HEREBY IRREVOCABLY WAIVE ANY AND ALL RIGHTS TO TRIAL BY JURY IN ANY LEGAL PROCEEDING
ARISING OUT OF OR RELATED TO THIS AGREEMENT. ANY ACTION OR PROCEEDING WHATSOEVER BETWEEN THE PARTIES HERETO RELATING TO THIS AGREEMENT
SHALL BE TRIED IN A COURT OF COMPETENT JURISDICTION BY A JUDGE SITTING WITHOUT A JURY.

 

Section 13.           Complete
Agreement; Inconsistent Agreements. This Agreement represents the complete agreement between the parties hereto as to all matters
covered hereby and supersedes any prior agreements or understandings between the parties.

 

Section 14.            Severability.
In the event any one or more of the provisions contained in this Agreement should be held invalid, illegal or unenforceable in
any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected
or impaired thereby (it being understood that the invalidity of a particular provision in a particular jurisdiction shall not in
and of itself affect the validity of such provision in any other jurisdiction). The parties shall endeavor in good-faith negotiations
to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as
possible to that of the invalid, illegal or unenforceable provisions.

 

    	 	6	 

     

    

 

Section 15.           Amendment
and Waiver. Except as otherwise provided herein, no modification, amendment or waiver of any provision of this Agreement shall
be effective against the Company or the Shareholder unless such modification is approved in writing by the Company and the Shareholder.
The failure of any party to enforce any of the provisions of this Agreement shall in no way be construed as a waiver of such provisions
and shall not affect the right of such party thereafter to enforce each and every provision of this Agreement in accordance with
its terms.

 

Section 16.           Enforcement.
Each of the parties hereto covenant and agree that the disinterested Directors of the Board have the right to enforce, waive or
take any other action with respect to this Agreement on behalf of the Company.

 

[SIGNATURE PAGES FOLLOW]

 

    	 	7	 

     

    

 

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement as a deed on the day and year first above written.

 

	 	Company:
	 	 
	 	Marker Therapeutics, Inc. (f/k/a TapImmune Inc.)

 

	 	By:	/s/ Peter Hoang
	 	Peter Hoang, CEO

 

Signature Page to Board Observer and
Director Nomination Agreement

 

     

     

    

 

	 	Shareholder:
	 	 
	 	New Enterprise Associates 16, L.P.
	 	By: NEA Partners 16, L.P.
	 	By: NEA 16 GP, LLC

 

	 	By:	/s/ Louis Citron
	 	Louis Citron, Chief Legal Officer

 

Signature Page to Board Observer and
Director Nomination Agreement

 

     

     

    

 

EXHIBIT 1

 

BOARD OBSERVER AND INDEMNIFICATION AGREEMENT

 

This Board Observer
and Indemnification Agreement (this “Agreement”) is made as of October 17, 2018 (the “Effective
Date”), between MARKER THERAPEUTICS, INC., a Delaware corporation formerly known as TapImmune, Inc., a Nevada corporation
(the “Company”), and ALI BEHBAHANI (“Observer”).

 

WHEREAS, pursuant
to a Board Observer and Director Nomination Agreement (the “Nomination Agreement”) dated as of the Effective
Date between the Company and New Enterprise Associates, Inc. (the “Shareholder”), the Shareholder has
the right to designate a non-voting observer who will be entitled to attend and participate in all meetings of the Company’s
Board of Directors (the “Board”), with such further rights and upon such further restrictions as set
forth in the Nomination Agreement; and

 

WHEREAS, the
Shareholder has appointed Observer as the non-voting observer pursuant to the Nomination Agreement.

 

NOW, THEREFORE, in consideration of the foregoing, and
in accordance with the terms of the Nomination Agreement, the Company and Observer hereby agree as follows:

 

1.            Board
Observer Rights.

 

(a)          The
Company agrees that it will invite Observer to attend, in a non-voting observer capacity, all meetings of the Board for the purposes
of permitting Observer to have current information with respect to the affairs of the Company and the actions taken by the Board
and Observer to provide input and advice with respect thereto (the “Approved Purposes”). Observer shall
have the right to be heard at any such meeting, but in no event shall Observer: (i) be deemed to be a member of the Board; (ii)
have the right to vote on any matter under consideration by the Board or otherwise have any power to cause the Company to take,
or not to take, any action; or (iii) except as expressly set forth in this Agreement, have or be deemed to have, or otherwise be
subject to, any duties (fiduciary or otherwise) to the Company or its stockholders or any duties (fiduciary or otherwise) otherwise
applicable to the directors of the Company.  As a non-voting observer, Observer will also be provided (concurrently with delivery
to the directors of the Company and in the same manner delivery is made to them) copies of all notices, minutes, consents, and
all other materials or information (financial or otherwise) that are provided to the directors with respect to a meeting or any
written consent in lieu of meeting (except to the extent Observer has been excluded therefrom pursuant to clause (c) below).

 

(b)          If
a meeting of the Board is conducted via telephone or other electronic medium (e.g., videoconference), Observer may attend such
meeting via the same medium; provided, however, that it shall be a material breach of this Agreement by Observer
to provide any other person access to such meeting without the Company’s express prior written consent (which consent may
be by e-mail).

 

(c)          Notwithstanding
the foregoing, the Company may exclude Observer from access to any material or meeting or portion thereof if: (i) the Board concludes
in good faith, upon advice of the Company’s counsel, that such exclusion is reasonably necessary to preserve the attorney-client
privilege between the Company and such counsel; provided, however, that any such exclusion shall apply only to such
portion of the material or such portion of the meeting which would be required to preserve such privilege and not to any other
portion thereof; or (ii) such portion of a meeting is an executive session limited solely to independent director members of the
Board, independent auditors and/or legal counsel, as the Board may designate, and Observer (assuming Observer were a member of
the Board) would not meet the then-applicable standards for independence adopted by the NASDAQ Capital Market, or such other exchange
on which the Company’s securities are then traded.

 

     

     

    

 

(d)          The
Company shall reimburse Observer for all reasonable out-of-pocket expenses incurred by Observer in connection with attendance at
Board meetings. All reimbursements payable by the Company pursuant to this Section 1(d) shall be paid to Observer in accordance
with the Company’s policies and practices with respect to director expense reimbursement then in effect; provided,
however, that any such reimbursement shall be paid to Observer no later than comparable compensation or reimbursement is
paid to the members of the Board.

 

(e)          The
rights described in this Section 1 shall terminate upon: (i) the occurrence of a Termination Event as defined in the Nomination
Agreement; (ii) any material violation of the terms of this Agreement by Observer which (A) remains uncured within ten business
days after receipt of notice thereof, or (B) if such violation is not subject to cure, directly causes harm to the Company in the
Board’s sole and absolute discretion; or (iii) the death or disability of Observer.

 

2.            Confidential
Treatment of Company Confidential Information.

 

(a)          In
consideration of the Company’s disclosure to Observer of information which is not publicly available concerning the Company
for the Approved Purposes, Observer agrees that this Agreement will apply to all information, in any form whatsoever, disclosed
or made available to Observer concerning the Company, its affiliates and/or the Approved Purposes (“Confidential Information”).

 

(b)          Except
as otherwise provided herein, Observer agrees: (i) to hold Confidential Information in strict confidence; (ii) not to disclose
Confidential Information to any third parties; and (iii) not to use any Confidential Information for any purpose except for the
Approved Purposes. Observer may disclose the Confidential Information to the Shareholder and its responsible agents, advisors,
affiliates and representatives with a bona fide need to know (“Representatives”), but only to the extent
necessary for the Approved Purposes. Observer agrees to instruct all such Representatives not to disclose such Confidential Information
to third parties without the prior written permission of the Company. Observer will, at all times, remain liable under the terms
of this Agreement for any unauthorized disclosure or use by any of its Representatives of Confidential Information provided to
such Representatives by Observer.

 

3.            Exempted
Disclosure. The foregoing restriction on the use and nondisclosure of Confidential Information will not include information
which: (i) is, or hereafter becomes, through no act or failure to act on the part of Observer, generally known or available to
the public; (ii) was acquired by Observer before receiving such information from the Company, without restriction as to use or
disclosure; (iii) is hereafter furnished to Observer by a third party, without, to Observer’s knowledge, restriction as to
use or disclosure; (iv) such information was independently developed by Observer; or (v) is required or requested to be disclosed
pursuant to judicial, regulatory or administrative process or court order, provided, that to the extent permitted by law,
rule or regulation and reasonably practicable under the circumstances, Observer gives the Company prompt notice of such required
disclosure so that the Company may challenge the same.

 

4.            Return
of Confidential Information. Following the termination of the rights of Observer described in Section 1 and upon request
of the Company, Observer will promptly: (i) return to the Company all physical materials containing or consisting of Confidential
Information and all hard copies thereof; and (ii) destroy all electronically stored Confidential Information in Observer’s
possession or control. Observer may retain in his confidential files one copy of any item of Confidential Information in order
to comply with any legal, compliance or regulatory requirements. Any Confidential Information that is not returned or destroyed,
including, without limitation, any oral Confidential Information, and all notes, analyses, compilations, studies or other documents
prepared by or for the benefit of Observer from such information, will remain subject to the confidentiality obligations set forth
in this Agreement indefinitely.

 

    	 	2	 

     

    

 

5.            Disclaimer.
All Confidential Information is provided to Observer “AS IS” and the Company does not make any representation or warranty
as to the accuracy or completeness of the Confidential Information or any component thereof. The Company will have no liability
to Observer resulting from the reliance on the Confidential Information by Observer or any third party to whom such Confidential
Information is disclosed.

 

6.            Company
Ownership of Confidential Information. Observer acknowledges that all of the Confidential Information is owned solely by the
Company (or its licensors) and that the unauthorized disclosure or use of such Confidential Information would cause irreparable
harm and significant injury, the degree of which may be difficult to ascertain. Therefore, in the event of any breach of this Agreement,
the Company is entitled to seek all forms of equitable relief (including an injunction and order for specific performance), in
addition to all other remedies available at law or in equity.

 

7.            Observer
and Representative Compliance with Securities Laws. Observer agrees that the Confidential Information is given in confidence
in accordance with the terms of this Agreement, and Observer will not take any action relating to the securities of the Company
which would constitute insider trading, market manipulation, or any other violation of applicable securities law. Observer agrees
to instruct all of his Representatives to whom he discloses Confidential Information that they may not take any action relating
to the securities of the Company which would constitute insider trading, market manipulation, or any other violation of applicable
securities law.

 

8.            Indemnity.
The Company will indemnify and hold harmless Observer from and against any losses, claims, damages, liabilities and expenses to
which Observer may become subject, insofar as such losses, claims, damages, liabilities or expenses (or actions in respect thereof)
arise out of, relate to, or are based upon Observer’s designation or attendance as a non-voting observer at meetings of the
Board, Observer’s receipt of materials or information under this Agreement, or Observer’s exercise of his rights under
this Agreement. The Company will pay or reimburse Observer for such losses, claims, damages, liabilities and expenses as they are
incurred, including, without limitation, for amounts incurred in connection with investigating or defending any such loss, claim,
damage, liability, expense or action. In furtherance of the rights set forth in this Section 8, the Company agrees that it will
enter into an Indemnification Agreement with Observer, which shall be on the form of the Indemnification Agreement provided to
each of the members of the Board.

 

9.            Insurance.
For the duration of Observer’s appointment as Observer of the Company, and thereafter for the duration of the applicable
statute of limitations, the Company shall cause to be maintained in effect a policy of liability insurance coverage for Observer
against liability that may be a Company shall provide Observer or his counsel with a copy of all directors’ liability insurance
applications, binders, policies, declarations, endorsements, and other related materials. Notwithstanding the foregoing, the Company
may, but shall not be required to, create a trust fund, grant a security interest, or use other means, including, without limitation,
a letter of credit, to ensure the payment of such amounts as may be necessary to satisfy its obligations to indemnify and advance
expenses pursuant to this Agreement.

 

    	 	3	 

     

    

 

10.           Governing
Law. All issues and questions concerning the construction, validity, interpretation and enforceability of this Agreement and
the exhibits and schedules hereto shall be governed by, and construed in accordance with, the laws of the State of Delaware, without
giving effect to any choice of law or conflict of law rules or provisions (whether of the State of Delaware or any other jurisdiction)
that would cause the application of the laws of any jurisdiction other than the State of Delaware.

 

11.           Notices.
Any notice provided for in this Agreement shall be in writing and shall be either personally delivered, or mailed first class mail
(postage prepaid, return receipt requested) or sent by reputable overnight courier service (charges prepaid) to the Company and
the Observer at the addresses set forth below. Notices shall be deemed to have been given hereunder when delivered personally,
three days after deposit in the U.S. mail and one day after deposit with a reputable overnight courier service.

 

If to the Company:

 

Marker Therapeutics, Inc.

5 W. Forsyth Street, Suite 200

Jacksonville FL 32202

Attention: CEO

 

with a copy to:

 

Seyfarth Shaw LLP

700 Milam, Suite 1400

Houston TX 77002

Attention: Paul Pryzant

 

If to the Observer:

 

Ali Behbahani

New Enterprise Associates, Inc.

5425 Wisconsin Ave, Suite 800

Chevy Chase, MD 20815

 

with a copy to:

 

New Enterprise Associates, Inc.

5425 Wisconsin Ave, Suite 800

Chevy Chase, MD 20815

Attention: Chief Legal Officer

 

12.           Entire
Agreement. This Agreement, together with the Nomination Agreement, constitutes the complete and exclusive statement regarding
the subject matter of this Agreement and supersedes all prior agreements, understandings and communications, oral or written, between
the parties regarding the subject matter of this Agreement.

 

    	 	4	 

     

    

 

13.           Term.
The provisions of Section 1 hereof shall terminate and be of no further force or effect pursuant to Section 1(e)
hereof. Notwithstanding the provisions of this Section 13, the provisions of Sections 2, 3, 4, 6,
7, 8, 9, 10, 12 and this Section 13 shall survive any termination or expiration of this Agreement.

 

[Remainder of page intentionally left
blank; signature page follows.]

 

    	 	5	 

     

    

 

IN
WITNESS WHEREOF, the undersigned have hereto executed this Agreement as of the date first above written.

 

	 	Company:
	 	 
	 	Marker Therapeutics, Inc. (f/k/a TapImmune Inc.)

 

	 	By:	 
	 	Peter Hoang, CEO

 

	 	Observer:

 

	 	 
	 	Ali Behbahani

 

Signature Page to Board Observer and
Indemnification Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00288-of-00352.parquet"}]]